Rhenman & Partners Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-136,000
| Closed | -$16.1M | – | 96 |
|
|
2022
Q1 | $16.1M | Sell |
136,000
-14,000
| -9% | -$1.66M | 1.59% | 25 |
|
|
2021
Q4 | $20.7M | Buy |
150,000
+15,000
| +11% | +$2.07M | 1.38% | 26 |
|
|
2021
Q3 | $18.8M | Sell |
135,000
-65,419
| -33% | -$9.09M | 1.32% | 30 |
|
|
2021
Q2 | $19.5M | Hold |
200,419
| – | – | 1.32% | 33 |
|
|
2021
Q1 | $13.7M | Sell |
200,419
-34,581
| -15% | -$2.36M | 0.96% | 42 |
|
|
2020
Q4 | $20.1M | Sell |
235,000
-75,000
| -24% | -$6.43M | 1.64% | 24 |
|
|
2020
Q3 | $20.2M | Buy |
310,000
+100,000
| +48% | +$6.5M | 1.79% | 20 |
|
|
2020
Q2 | $15.4M | Buy |
210,000
+70,000
| +50% | +$5.12M | 1.66% | 22 |
|
|
2020
Q1 | $4.76M | Buy |
140,000
+15,000
| +12% | +$510K | 0.67% | 54 |
|
|
2019
Q4 | $6.81M | Buy |
+125,000
| New | +$6.81M | 0.75% | 56 |
|